Goldman Sachs’s Apellis Pharmaceuticals APLS Stock Holding History

Goldman Sachs’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,000	Closed	-$364K	–	6322
2025 Q2	$364K	Buy	+21,000	New	+$389K	﹤0.01%	5345
2023 Q3	–	Sell	-23,400	Closed	-$2.13M	–	5525
2023 Q2	$2.13M	Buy	+23,400	New	+$2.02M	﹤0.01%	3835
2023 Q1	–	Sell	-15,000	Closed	-$776K	–	5895
2022 Q4	$776K	Buy	+15,000	New	+$796K	﹤0.01%	4589
2020 Q2	–	Sell	-20,000	Closed	-$536K	–	5180
2020 Q1	$536K	Buy	20,000 +7,700	+63%	+$273K	﹤0.01%	4174
2019 Q4	$377K	Buy	+12,300	New	+$340K	﹤0.01%	4649

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's APLS Position: Q2 2026 in Review

Goldman Sachs sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,980,144 shares — an estimated $79.7M sold.

Goldman Sachs first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $79.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Goldman Sachs reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 1,980,144 Apellis Pharmaceuticals shares in Q2 2026, an estimated $79.7M.
Goldman Sachs first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
Goldman Sachs's Apellis Pharmaceuticals position peaked at $79.7M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.